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Distal renal tubular 
acidosis and mutation 
in the H+-ATPase
The genetic syndromes that result in 
distal renal tubular acidosis (RTA) 
are produced by mutations several 
genes, including one of the compo-
nents of the vacuolar H+-ATPase, the 
enzyme responsible for H+ secretion 
into the urine. The catalytic sector of 
this enzyme is composed of a large 
number of subunits, two of which are 
highly expressed in the intercalated cell 
of the collecting tubule. Mutations in 
one such subunit, B1, have been associ-
ated with distal RTA. In this issue, Fus-
ter et al. report a new mutation in the 
C terminus of this protein. The authors’ 
elegant biochemical analysis shows that 
this mutation prevents the assembly of 
the catalytic sector of the ATPase. They 
analyzed 12 reported missense muta-
tions in the B1 subunit and found that 
many of them produced the same phe-
notype: the failure of assembly, leading 
to no proton pumping. The assays of 
proton pumping and pump assembly 
provide the best possible analysis for 
the role of these mutations in causing 
distal RTA. See page 1151.
Intestinal oxalate 
absorption  
in stone formers
Oxalate, produced by the liver, is present 
in many foodstuﬀs. Hence, patients with 
calcium oxalate nephrolithiasis who 
excrete large amounts of oxalate in the 
urine may do so because of overpro-
duction of oxalate by the liver or hyper-
reabsorption by the intestine. Although 
the latter can be secondary to intesti-
nal diseases, it is primarily idiopathic. 
Sikora et al. conducted a study in which 
13C-oxalate was given to patients with 
calcium oxalate nephrolithiasis under 
standard dietary conditions. Calcium 
oxalate stone formers absorbed larger 
amounts of oxalate than did controls or 
patients with primary hyperoxaluria. 
Oxalate hyperabsorption was seen in 
one-third of the patients with idiopathic 
stone disease. Remarkably, patients with 
idiopathic hyperoxaluria did not hyper-
absorb oxalate, suggesting that restricting 
their oxalate intake is not mandatory 
except in the case of foods with high 
oxalate content. See page 1181.
Cyclosporine therapy 
in nephrotic children
Cyclosporine is now a standard treat-
ment for nephrotic syndrome. Ishikura 
et al. studied its efficacy and safety 
in children with the relapsing vari-
ety. A group of patients were given 
cyclosporine; some received a fixed 
dose, whereas others received doses 
adjusted to achieve a trough level of 
60–80 ng/ml. In those who received the 
adjusted dose, the rate of remission was 
higher and the hazard ratio was lower 
than in those who received the fixed 
dose. This ﬁnding suggests that manag-
ing children with relapsing nephrotic 
syndrome by maintaining a targeted 
level of cyclosporine is both eﬀective 
and safe. See page 1167.
